Shorter chemo shows promise for kids with hodgkin lymphoma

NCT ID NCT00846742

Ongoing Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a shorter, more intense chemotherapy regimen called Stanford V in children and young adults with favorable Hodgkin lymphoma. Those who still have signs of cancer after 8 weeks of chemo also receive low-dose radiation to the affected areas. The goal is to see if this approach can improve the complete response rate while reducing the need for longer treatment and its side effects. The study enrolled 88 participants aged 21 and younger.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stanford V chemotherapy (a combination of vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide, and prednisone) with or without low-dose radiation therapy
What this could lead to: If successful, this could offer a shorter, less toxic treatment option for children with favorable Hodgkin lymphoma, potentially reducing long-term side effects while maintaining high cure rates.
What could go wrong: This is a phase 2 trial with only 88 participants, so results are preliminary. The chemotherapy still carries risks like infection, bleeding, and fertility issues, and some children may still need radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Children's Hospital of Illinois at OSF St. Francis Medical Center

Peoria, Illinois, 61637, United States
Dana-Farber Harvard Cancer Center

Boston, Massachusetts, 02115, United States
Maine Children's Cancer Program (MCCP)

Scarborough, Maine, 04074, United States
Packard Children's Hospital, Stanford University

Palo Alto, California, 94304, United States
Rady Children's Hospital- San Diego

San Diego, California, 92123, United States
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.